Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Feb;29(2):325–326. doi: 10.1128/aac.29.2.325

In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.

S M Smith
PMCID: PMC176400  PMID: 2940966

Abstract

Seven quinolone antibiotics were tested against 115 isolates of methicillin-resistant Staphylococcus aureus. The MICs for 90% of the strains tested were 0.5 microgram/ml for A-56619, A-56620, ciprofloxacin, and ofloxacin; 2.0 micrograms/ml for amifloxacin and enoxacin; and 4.0 micrograms/ml for norfloxacin. Killing kinetic studies showed a similar killing rate for all seven antibiotics.

Full text

PDF
325

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauernfeind A., Petermüller C. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol. 1983 Apr;2(2):111–115. doi: 10.1007/BF02001575. [DOI] [PubMed] [Google Scholar]
  2. Boscia J. A., Kobasa W. D., Kaye D. Enoxacin compared with cefoperazone for the treatment of experimental Enterobacter aerogenes endocarditis. Antimicrob Agents Chemother. 1985 May;27(5):708–711. doi: 10.1128/aac.27.5.708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chin N. X., Neu H. C. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother. 1983 Nov;24(5):754–763. doi: 10.1128/aac.24.5.754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Goldstein E. J., Alpert M. L., Ginsberg B. P. Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections. Antimicrob Agents Chemother. 1985 Mar;27(3):422–423. doi: 10.1128/aac.27.3.422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Jacobus N. V., Tally F. P., Barza M. Antimicrobial spectrum of Win 49375. Antimicrob Agents Chemother. 1984 Jul;26(1):104–107. doi: 10.1128/aac.26.1.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Locksley R. M., Cohen M. L., Quinn T. C., Tompkins L. S., Coyle M. B., Kirihara J. M., Counts G. W. Multiply antibiotic-resistant Staphylococcus aureus: introduction, transmission, and evolution of nosocomial infection. Ann Intern Med. 1982 Sep;97(3):317–324. doi: 10.7326/0003-4819-97-3-317. [DOI] [PubMed] [Google Scholar]
  7. Nakamura S., Minami A., Katae H., Inoue S., Yamagishi J., Takase Y., Shimizu M. In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid. Antimicrob Agents Chemother. 1983 May;23(5):641–648. doi: 10.1128/aac.23.5.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ramirez C. A., Bran J. L., Mejia C. R., Garcia J. F. Open, prospective study of the clinical efficacy of ciprofloxacin. Antimicrob Agents Chemother. 1985 Jul;28(1):128–132. doi: 10.1128/aac.28.1.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Saravolatz L. D., Pohlod D. J., Arking L. M. Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks. Ann Intern Med. 1982 Sep;97(3):325–329. doi: 10.7326/0003-4819-97-3-325. [DOI] [PubMed] [Google Scholar]
  10. Sato K., Matsuura Y., Inoue M., Une T., Osada Y., Ogawa H., Mitsuhashi S. In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother. 1982 Oct;22(4):548–553. doi: 10.1128/aac.22.4.548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Smith S. M., Eng R. H. Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1985 May;27(5):688–691. doi: 10.1128/aac.27.5.688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sullam P. M., Täuber M. G., Hackbarth C. J., Chambers H. F., Scott K. G., Sande M. A. Pefloxacin therapy for experimental endocarditis caused by methicillin-susceptible or methicillin-resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother. 1985 May;27(5):685–687. doi: 10.1128/aac.27.5.685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Watanakunakorn C. Treatment of infections due to methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982 Sep;97(3):376–378. doi: 10.7326/0003-4819-97-3-376. [DOI] [PubMed] [Google Scholar]
  14. Wenzel R. P. The emergence of methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982 Sep;97(3):440–442. doi: 10.7326/0003-4819-97-3-440. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES